Mevlut Kurt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mevlut Kurt has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Sercan Aksoy
Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara 06100, Turkey
4 shared publications - Kadri Altundag
Hacettepe University Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey
2 shared publications Nilufer Guler
Department of Medical Oncology, Institute of Oncology, Faculty of Medicine, Hacettepe University
2 shared publications- Ali Shorbagi
Department of Internal Medicine, Faculty of Medicine, Hacettepe University
1 shared publication - Cagatay Arslan
Department of Medical Oncology, Faculty of Medicine, Izmir Ekonomi University, Medical Park Hospital, 35330 Izmir, Türkiye
1 shared publication Ibrahim Güllü
1 shared publication
Latest Publications
- 11 February 2012
- Vol. 97 (2011Novemb) , 711-6
Increased mean corpuscular volume of erythrocytes during capecitabine treatment: a simple surrogate marker for clinical response
Capecitabine, as all fluoropyrimidines, interferes with vitamin metabolism and may thus have an impact on hematopoiesis. It is metabolized to its active form 5-fluoruracil by the enzyme thymidine phosphorylase, which exists in higher concentrations in tumor tissue and liver than in normal tissues. In the study, we investigated the changes in mean corpuscular volume (MCV) of red blood cells and the possible correlation of these changes with the clinical outcome of capecitabine treatment in women with metastatic breast cancer. Data from 75 metastatic breast cancer patients were analyzed retrospectively. Capecitabine was used at a dose of 2500 mg/m² daily for 14 days of every 3-week period. Mean corpuscular volume of red blood cells and other parameters of complete blood count were recorded at the beginning of the treatment, in the ninth week, and periodically thereafter. Mean age was 51.5 ± 10.8 and 61.3% of the patients were premenopausal. Capecitabine was administered as the median 3rd line (min-max: 1-9) treatment and a median of 6 cycles (min-max: 1-24) for metastatic breast cancer. Median ΔMCV level (post-treatment values at ninth week - baseline) was 8. ΔMCV was ≥8 in 37 patients and <8 in 38 patients. The 35 of the 37 patients with ΔMCV level ≥8 and 25 of the 38 patients with ΔMCV level <8 had clinical benefit (complete response + partial response + stable disease) from capecitabine treatment (P = 0.02). However, the difference between progression-free survival of the patients with ΔMCV levels higher than 8 and those with ΔMCV levels lower than 8 according to Kaplan-Meier survival analysis was not statistically significant (6.7 and 4.3 months, respectively, P = 0.26). Additionally, median ΔMCV level was 9.1 (min-max: -2.4 to 24.9) among patients who had clinical benefit and 5.90 (min-max: -0.8 to 12.3) among nonresponders (P = 0.016). Capecitabine increases the mean corpuscular volume levels of red blood cells by a yet unidentified mechanism. Early increment of mean corpuscular volume levels is higher than 8, i.e. by the 9th week, might predict clinical benefit from the treatment.
- 11 February 2012
- Vol. 97 (2011Novemb) , 711-6
Increased mean corpuscular volume of erythrocytes during capecitabine treatment: a simple surrogate marker for clinical response
Capecitabine, as all fluoropyrimidines, interferes with vitamin metabolism and may thus have an impact on hematopoiesis. It is metabolized to its active form 5-fluoruracil by the enzyme thymidine phosphorylase, which exists in higher concentrations in tumor tissue and liver than in normal tissues. In the study, we investigated the changes in mean corpuscular volume (MCV) of red blood cells and the possible correlation of these changes with the clinical outcome of capecitabine treatment in women with metastatic breast cancer. Data from 75 metastatic breast cancer patients were analyzed retrospectively. Capecitabine was used at a dose of 2500 mg/m² daily for 14 days of every 3-week period. Mean corpuscular volume of red blood cells and other parameters of complete blood count were recorded at the beginning of the treatment, in the ninth week, and periodically thereafter. Mean age was 51.5 ± 10.8 and 61.3% of the patients were premenopausal. Capecitabine was administered as the median 3rd line (min-max: 1-9) treatment and a median of 6 cycles (min-max: 1-24) for metastatic breast cancer. Median ΔMCV level (post-treatment values at ninth week - baseline) was 8. ΔMCV was ≥8 in 37 patients and <8 in 38 patients. The 35 of the 37 patients with ΔMCV level ≥8 and 25 of the 38 patients with ΔMCV level <8 had clinical benefit (complete response + partial response + stable disease) from capecitabine treatment (P = 0.02). However, the difference between progression-free survival of the patients with ΔMCV levels higher than 8 and those with ΔMCV levels lower than 8 according to Kaplan-Meier survival analysis was not statistically significant (6.7 and 4.3 months, respectively, P = 0.26). Additionally, median ΔMCV level was 9.1 (min-max: -2.4 to 24.9) among patients who had clinical benefit and 5.90 (min-max: -0.8 to 12.3) among nonresponders (P = 0.016). Capecitabine increases the mean corpuscular volume levels of red blood cells by a yet unidentified mechanism. Early increment of mean corpuscular volume levels is higher than 8, i.e. by the 9th week, might predict clinical benefit from the treatment.
- 1 May 2007
- Vol. 52 (5) , 425-7
Gastric cancer and the coincidental finding of herpetic esophagitis immediately after pregnancy: a case report.
Gastric cancer associated with pregnancy is extremely rare and usually diagnosed at an advanced stage. A 22-year-old woman was admitted to the hospital with complaints of dysphagia, retrosternal pain, nausea, vomiting and abdominal pain. Esophagogastroduodenoscopic biopsy revealed herpetic esophagitis and signet-ring cell carcinoma of the stomach. Early recognition and diagnosis of gastric cancer during pregnancy is the only possibility for a positive outcome.
- 1 May 2007
- Vol. 52 (5) , 425-7
Gastric cancer and the coincidental finding of herpetic esophagitis immediately after pregnancy: a case report.
Gastric cancer associated with pregnancy is extremely rare and usually diagnosed at an advanced stage. A 22-year-old woman was admitted to the hospital with complaints of dysphagia, retrosternal pain, nausea, vomiting and abdominal pain. Esophagogastroduodenoscopic biopsy revealed herpetic esophagitis and signet-ring cell carcinoma of the stomach. Early recognition and diagnosis of gastric cancer during pregnancy is the only possibility for a positive outcome.
- 1 October 2006
- Published by Wiley in International Journal of Dermatology
- Vol. 45 (10) , 1263-1265
Malignant eccrine poroma presenting with pulmonary and liver metastases
- 1 October 2006
- Published by Wiley in International Journal of Dermatology
- Vol. 45 (10) , 1263-1265
Malignant eccrine poroma presenting with pulmonary and liver metastases
- 1 February 2006
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 40 (2) , 328-331
Capecitabine-Induced Severe Hypertriglyceridemia: Report of Two Cases
Objective: To report 2 cases of severe hypertriglyceridemia associated with the use of oral capecitabine. Case Summaries: The first patient was a 73-year-old woman with metastatic breast carcinoma who received capecitabine 2500 mg/m 2 /day in 2 divided doses for 2 weeks followed by a one week rest period. The baseline triglyceride level was 324 mg/dL; after 2 cycles of capecitabine, levels increased to 916 mg/dL. Although lipid-lowering treatment was initiated, triglyceride levels peaked at 1782 mg/dL by the end of the seventh cycle. Eight weeks after capecitabine treatment was stopped, triglyceride levels decreased to 118 mg/dL. The second patient was a 59-year-old man with metastatic colorectal carcinoma who was placed on capecitabine treatment at a dosage of 2500 mg/m 2 /day in 2 divided doses for 2 weeks followed by a one week rest period. The baseline triglyceride level was 244 mg/dL; levels peaked at 1455 mg/dL at the end of the fifth cycle. Capecitabine treatment was discontinued due to disease progression, and triglyceride levels decreased to 154 mg/dL after 11 weeks. Discussion: The most frequently reported adverse effects of capecitabine are gastrointestinal and hematologic effects and palmar-plantar erythrodysesthesia. Drug-induced hyperlipidemia may appear more readily in individuals with hereditary lipoprotein lipase deficiency because decreased lipoprotein lipase activity might make these individuals more susceptible to a rise in triglyceride levels. The Naranjo probability scale indicated a probable relationship between capecitabine and severe hypertriglyceridemia. Conclusions: Capecitabine should be prescribed with care, especially in patients with preexisting hypertriglyceridemia. The question of whether capecitabine actually causes hypertriglyceridemia needs careful consideration, and the possible mechanism by which it may cause this adverse effect requires further investigation.
- 1 February 2006
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 40 (2) , 328-331
Capecitabine-Induced Severe Hypertriglyceridemia: Report of Two Cases
Objective: To report 2 cases of severe hypertriglyceridemia associated with the use of oral capecitabine. Case Summaries: The first patient was a 73-year-old woman with metastatic breast carcinoma who received capecitabine 2500 mg/m 2 /day in 2 divided doses for 2 weeks followed by a one week rest period. The baseline triglyceride level was 324 mg/dL; after 2 cycles of capecitabine, levels increased to 916 mg/dL. Although lipid-lowering treatment was initiated, triglyceride levels peaked at 1782 mg/dL by the end of the seventh cycle. Eight weeks after capecitabine treatment was stopped, triglyceride levels decreased to 118 mg/dL. The second patient was a 59-year-old man with metastatic colorectal carcinoma who was placed on capecitabine treatment at a dosage of 2500 mg/m 2 /day in 2 divided doses for 2 weeks followed by a one week rest period. The baseline triglyceride level was 244 mg/dL; levels peaked at 1455 mg/dL at the end of the fifth cycle. Capecitabine treatment was discontinued due to disease progression, and triglyceride levels decreased to 154 mg/dL after 11 weeks. Discussion: The most frequently reported adverse effects of capecitabine are gastrointestinal and hematologic effects and palmar-plantar erythrodysesthesia. Drug-induced hyperlipidemia may appear more readily in individuals with hereditary lipoprotein lipase deficiency because decreased lipoprotein lipase activity might make these individuals more susceptible to a rise in triglyceride levels. The Naranjo probability scale indicated a probable relationship between capecitabine and severe hypertriglyceridemia. Conclusions: Capecitabine should be prescribed with care, especially in patients with preexisting hypertriglyceridemia. The question of whether capecitabine actually causes hypertriglyceridemia needs careful consideration, and the possible mechanism by which it may cause this adverse effect requires further investigation.
- Open Access
- 1 January 2006
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 45 (5) , 625-626
Could the hand-foot syndrome after capecitabine treatment be associated with better outcome in metastatic breast cancer patients?
(2006). Could the hand-foot syndrome after capecitabine treatment be associated with better outcome in metastatic breast cancer patients? Acta Oncologica: Vol. 45, No. 5, pp. 625-626.
- 1 January 2006
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 45 (5) , 625-626
Open AccessCould the hand-foot syndrome after capecitabine treatment be associated with better outcome in metastatic breast cancer patients?
(2006). Could the hand-foot syndrome after capecitabine treatment be associated with better outcome in metastatic breast cancer patients? Acta Oncologica: Vol. 45, No. 5, pp. 625-626.